Hi, I'm Dan Premack, and welcome to Axios Recap, presented by Google.

Today is Friday, October 16th.

U.S. retail sales are up, U.S. industrial production is down, and we're focused on Operation

Warp Speed.

Earlier today, drug maker Pfizer announced that it won't apply for an emergency use authorization

for its COVID-19 vaccine until late November at the earliest.

That's kind of the same thing that Mederina said a few weeks back, and all but guarantees

that the FDA won't be asked to even think about approval until weeks

or maybe even months after the election. Now, to some extent, that's good news because it

removes some of the feared politicization from the process. Of course, it also means the vaccine

won't be ready as early as President Trump had claimed it would be. And if you were a

business or a school that was banking on Trump's word on this, you might now have to prepare for

some delays. So we want to go deeper with Moncef Slui, the former head of Glaxo-Smith-Kline's

vaccine division who currently serves as the White House's top scientific advisor to Operation Warp Speed,

which is the public-private partnership in charge of getting a coronavirus vaccine developed

and deployed. That conversation in 15 seconds.

We're joined now by Moncef Slawe, the White House chief scientific advisor to Operation Warp Speed.

Can we start here?

What is the latest timeline for actually getting a vaccine application for approval?

Not approval, but an application for approval.

First, good news is Moderna trial is almost fully recruited

and very likely to complete recruitment next week.

...